Anaemia and heart failure: Is its correction a therapeutic target? The role of erythropoietin

Hellenic Journal of Cardiology

Volumn 46, Issue 3, 2005, Pages 222-225

  Kallergis, Eleftherios M ^a   Mavrakis, Hercules E ^a   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Anaemia; Erythropoietin; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ERYTHROPOIETIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTIOXIDANT ACTIVITY; DISEASE ASSOCIATION; HEART FAILURE; HUMAN; IRON DEFICIENCY; MALABSORPTION; PROGNOSIS; REVIEW; CONGESTIVE HEART FAILURE; INCIDENCE; MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 24644492510     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Ho KK, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22:6A
2. O'Connell JB, Bristow M: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1993; 13: S107-112.
3. Haldeman GA, Croft JB, Giles WH, Rashidee A: Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999; 137: 352-360.
4. Mehra MR, Uber PA, Francis GS: Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J Am Coll Cardiol 2003; 41: 1606-1610.
5. Silverberg DS, Wexler D, Blum M, et al: Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perinat Dial Int 2001; 21 (Suppl 3): pp. S236-240.
6. Anand IS, Chandrashekhar Y, Ferrari R, et al: Pathogenesis of oedema in chronic anaemia: studies of body water and sodium, renal function, haemodynamics and plasma hormones. Br Heart J 1993; 70: 357-362.
7. Silverberg DS, Wexler D, Blum M, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalization. J Am Coll Cardiol 2000; 35: 1737-1744.
8. Chatterjee B, Nydegger UE, Mohacsi P: Serum erythropoietin in heart failure patients treated with ACE inhibitors or AT1 antagonists. Eur J Heart Fail 2000; 2: 393-398.
9. Iverson PO, Wolbaek PR, Tonnessen T, Christensen G: Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol 2002; 282: R166-172.
10. Tanner H, Moschovitis G, Kuster GM, et al: The prevalence of anemia in chronic heart failure. Int J Cardiol 2002; 86: 115-121.
11. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003; 107: 223-225.
12. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39: 1780-1786.
13. Kosborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM: The prognostic importance of anemia in patients with heart failure. Am J Med 2003; 114: 112-119.
14. Kratz A, Lewandrowski KB: Normal reference laboratory values. N Engl J Med 1998; 339: 1063-1072.
15. Volpe M, Tritto C, Testa U, et al: Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994; 74: 468-473.
16. Silverberg DS, Wexler D, Iaina A: The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 2002; 4: 681-686.
17. Weiss G: Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16: 87-96.
18. Okonko DO, Anker SD: Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 2004; 10: S5-S9.
19. Obayashi K, Ando Y, Terazaki H, et al: Mechanism of anemia associated with autonomic dysfunction in rats. Auton Neurosci 2000; 82: 123-129.
20. Katz AM: The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Int Med 1994; 121: 363-371.
21. Johnson DB, Dell'Italia LJ: Cardiac hypertrophy and failure in hypertension. Curr Opin Nephrol Hypertension 1996; 5: 186-191.
22. Al-Ahmad A, Rand WM, Manjunath G, et al: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955-962.
23. Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). J Am Coll Cardiol 2003; 41: 1933-1939.
24. Felker GM, Gattis WA, Leimberger JD, et al: Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003; 92: 625-628.
25. Drazner MH, Rame JE, Stevenson LW, Dries DL: Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345: 574-581.
26. Maeda K, Tsutamoto T, Wada A, et al: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-1593.
27. Bommer J, Kugel M, Schoeppe W, et al: Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol 1988; 66: 85-93.
28. Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W: Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11: 54-60.
29. Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA: Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992; 124: 424-427.
30. Linde T, Wikstrom B, Andersson LG, Danielson BG: Renal anemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischemic heart disease. Scand J Urol Nephrol 1996; 30: 115-120.
31. Silverberg DS, Wexler D, Sheps D, et al: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-1780.
32. Mancini DM, Katz SD, Lamanca J, Lamanca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-299.
33. Laura Calvillo, Roberto Latini, Jan Kajstura, et al: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-4806.
34. Siren AL, Fratelli M, Brines M, et al: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98: 4044-4049.
35. Celik M, Gokmen N, Erbayraktar S, et al: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 2002; 99: 2258-2263.
36. Ehrenreich H, Hasselblat M, Dembowski C, et al: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002; 8: 495-505.
37. Cai Z, Manalo DJ, Wei G, et al: Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003; 108: 79-85.
38. Parsa CJ, Matsumoto A, Kim J, et al: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007.
39. Tramontano AF, Muniyappa R, Black AD, et al: Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003; 308: 990-994.
40. Moon C, Krawczyk M, Ahn D, et al: Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003; 100: 11612-11617.